Although adverse effects may occur, selective serotonin reuptake inhibitors are generally well tolerated in the elderly

Drugs and Therapy Perspectives

Volumn 25, Issue 5, 2009, Pages 19-22

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CHOLINERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; DEXTROMETHORPHAN; DIURETIC AGENT; ESCITALOPRAM; FLUOXETINE; FLUPHENAZINE; FLUVOXAMINE; HALOPERIDOL; LINEZOLID; LITHIUM; MONOAMINE OXIDASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; NORFLUOXETINE; PAROXETINE; RITONAVIR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TAMOXIFEN; THEOPHYLLINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRYPTOPHAN; WARFARIN;

AGITATION; ALOPECIA; ANOREXIA; ANORGASMIA; ANXIETY DISORDER; BONE DENSITY; CARDIOVASCULAR EFFECT; CENTRAL NERVOUS SYSTEM; COGNITIVE DEFECT; COMA; CONSTIPATION; DELIRIUM; DEPRESSION; DIAPHORESIS; DIARRHEA; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG EXCRETION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; DYSPHONIA; ECCHYMOSIS; EJACULATION DISORDER; EPISTAXIS; ERECTILE DYSFUNCTION; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; FATIGUE; GALACTORRHEA; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERREFLEXIA; HYPONATREMIA; IMPOTENCE; INSOMNIA; INTESTINE MOTILITY; KIDNEY CLEARANCE; LIBIDO; LIVER CLEARANCE; MANIA; MENTAL HEALTH; MYOCLONUS; MYOGLOBINURIA; NAUSEA; NERVOUSNESS; NOCTURIA; NUTRITIONAL STATUS; PARKINSONISM; PHARMACOGENETICS; PSYCHOSIS; PURPURA; RASH; RECEPTOR AFFINITY; RESTLESSNESS; REVIEW; RHABDOMYOLYSIS; RISK; SEIZURE; SEROTONIN SYNDROME; SEXUAL DYSFUNCTION; SHIVERING; SIDE EFFECT; STROKE; SUICIDAL BEHAVIOR; TREMOR; URINE INCONTINENCE; URINE RETENTION; WEIGHT REDUCTION;

EID: 64849101494     PISSN: 11720360     EISSN: None     Source Type: Journal    
DOI: 10.2165/0042310-200925050-00006     Document Type: Review

References (19)

1. Draper B, Berman K. Tolerability of selective serotonin reuptake inhibitors: issues relevant to the elderly. Drugs Aging 2008; 25 (6): 501-19
2. Naranjo CA, Herrmann N, Mittmann N, et al. Recent advances in geriatric psychopharmacology. Drugs Aging 1995 Sep; 7 (3): 184-202
3. Nieuwstraten C, Labiris NR, Holbrook A. Systematic overview of drug interactions with antidepressant medications. Can J Psychiatry 2006 Apr; 51 (5): 300-16
4. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors: an overview with emphasis on pharmaco-kinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997; 32 Suppl. 1: 1-21
5. Rigler SK, Webb MJ, Redford L, et al. Weight outcomes among antidepressant users in nursing facilities. J Am Geriatr Soc 2001 Jan; 49 (1): 49-55
6. Lake MB, Birmaher B, Wassick S, et al. Bleeding and selective serotonin reuptake inhibitors in childhood and adolescence. J Child Adolesc Psychopharmacol 2000; 10 (1): 35-8
7. Bull SA, Hu XH, Hunkeler EM, et al. Discontinuation of use and switching of antidepressants: influence of patient-physician communication. JAMA 2002 Sep 18; 288 (11): 1403-9
8. Murphy Jr GM, Hollander SB, Rodrigues HE, et al. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry 2004 Nov; 61 (11): 1163-9
9. Patel R. Clinical comparison of SSRIs in the treatment of geriatric depression: a review of the literature. Rev Clin Gerontol 2000 Nov; 10 (4): 349-73
10. van de Vijver DAMC, Roos RAC, Jansen PAF, et al. Start of a selective serotonin reuptake inhibitor (SSRI) and increase of an-tiparkinsonian drug treatment in patients on levodopa. Br J Clin Pharmacol 2002 Aug; 54 (2): 168-70
11. Wilson K, Mottram P. A comparison of side effects of selective serotonin reuptake inhibitors and tricyclic antidepressants in older depressed patients: a meta-analysis. Int J Geriatr Psychiatry 2004 Aug; 19 (8): 754-62
12. Ramasubbu R. Cerebrovascular effects of selective serotonin reup-take inhibitors: a systematic review. J Clin Psychiatry 2004 Dec; 65 (12): 1642-53
13. Hubbard R, Farrington P, Smith C, et al. Exposure to tricyclic and selective serotonin reuptake inhibitor antidepressants and the risk of hip fracture. Am J Epidemiol 2003 Jul 1; 158 (1): 77-84
14. Richards JB, Papaioannou A, Adachi JD, et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med 2007 Jan 22; 167 (2): 188-94
15. Votolato NA, Stern S, Caputo RM. Serotonergic antidepressants and urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2000 Dec; 11 (6): 386-8
16. Mercke Y, Sheng H, Khan T, et al. Hair loss in psychopharmaco-logy. Ann Clin Psychiatry 2000 Mar; 12 (1): 35-42
17. Jacob S, Spinler SA. Hyponatremia associated with selective sero-tonin-reuptake inhibitors in older adults. Ann Pharmacother 2006 Sep; 40 (9): 1618-22
18. Friedman R, Leon A. Expanding the black box: depression, antide-pressants, and the risk of suicide. N Engl J Med 2007; 356 (23): 2343-6
19. Juurlink DN, Mamdani MM, Kopp A, et al. The risk of suicide with selective serotonin reuptake inhibitors in the elderly. Am J Psychiatry 2006 May; 163 (5): 813-21